Tiziana Life Sciences Ltd’s recent April 2026 disclosures highlight progress in its intranasal anti-CD3 antibody program (Foralumab) with preclinical evidence showing benefits in a Long COVID neuroinflammation model. Concurrently, the company secured $8.6 million net proceeds in a January 2026 equity raise, aimed at advancing its Phase 2a clinical trials targeting neurodegenerative diseases including SPMS and MSA. While still pre-revenue and reliant on external funding, Tiziana is positioned in a high unmet need therapeutic area with proprietary technology and committed pipeline investments. Key challenges include clinical trial outcomes, regulatory approval timelines, and ongoing capital requirements.